Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:274584.
doi: 10.1155/2014/274584. Epub 2014 May 27.

HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas

M J Rutten  1 , F Dijk  2 , C D Savci-Heijink  2 , M R Buist  1 , G G Kenter  1 , M J van de Vijver  2 , E S Jordanova  3
Affiliations

HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas

M J Rutten et al. J Immunol Res. 2014.

Abstract

Aberrant expression of human leukocyte antigens (HLA) class I has prognostic importance in various cancers. Here, we evaluated the prognostic value of classical (A/B/C) and nonclassical (G/E) HLA expression in 169 high grade epithelial ovarian cancer samples and linked that to clinicopathological characteristics and survival. Expression of HLA-A, -B/C, or -E was not correlated with survival. Survival was prolonged when tumours expressed HLA-G (P = 0.008) and HLA-G was an independent predictor for better survival (P = 0.011). In addition, HLA-G expression was associated with longer progression-free survival (P = 0.036) and response to chemotherapy (P = 0.014). Accordingly, high expression of HLA-G mRNA was associated with prolonged disease-free survival (P = 0.037) in 65 corresponding samples. Elevated serum-soluble HLA-G levels as measured by enzyme-linked immunosorbent assay in 50 matched patients were not correlated to HLA-G protein expression or gene expression nor with survival. During treatment, sHLA-G levels declined (P = 0.038). In conclusion, expression of HLA-G is an independent prognostic factor for improved survival in high grade epithelial ovarian cancer and a predictor for platinum sensitivity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative examples of HLA immunohistochemical staining, HLA-A ((a)–(c)), HLA-B/C ((d)–(f)), HLA-E ((h)–(j)), and HLA-G ((i)-(j)). Strong expression ((a), (d), (g), and (i)), weak expression ((b) and (e)), and loss of expression ((c), (f), (h), and (j)).
Figure 2
Figure 2
Survival analyses. Kaplan-Meier 5-year survival curves and log-rank test for HLA-G expression (a), HLA-A expression (b), HLA-G expression in tumours with downregulation of HLA-A (c), and HLA-G gene expression at the median expression cut-off of 230.4 fluorescence units (d) (NS = not significant).
Figure 3
Figure 3
Median concentration of sHLA-G (u/mL) at diagnosis, after 2 cycles of chemotherapy, after primary treatment, and at recurrence. ⊥ is the lowest interquartile and ⊤ is the highest interquartile.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer Journal for Clinicians. 2012;62(1):10–29. - PubMed
    1. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews. 2011;(8):p. CD007565. - PMC - PubMed
    1. Braicu E-I, Sehouli J, Richter R, Pietzner K, Denkert C, Fotopoulou C. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. British Journal of Cancer. 2011;105(12):1818–1824. - PMC - PubMed
    1. Winter WE, III, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology. 2008;26(1):83–89. - PubMed
    1. Kurman RJ, Shih I-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Human Pathology. 2011;42(7):918–931. - PMC - PubMed

MeSH terms

Substances